A global, U.S.-based emerging biopharmaceutical manufacturer that was months away from launching their first drug in the U.S.
The client decided not to invest in the infrastructure and systems, but recognized that they needed to comply with U.S. government regulations. Senior leadership recognized the risks of non-compliance in this complex area and needed an outsourced solution and team they could trust.
The immediate result was having their drugs covered in the various programs at time of launch. In addition, it provided a lower cost and footprint for the company to maintain. It also provided the company trusted advisors that could not only perform the necessary steps for their Centers for Medicare & Medicaid Services (CMS) and Veterans Affairs (VA) reporting, but also provide additional analysis prospectively with a team that understands their products and company.